Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes

Journal of Dermatological Science

Volumn 67, Issue 2, 2012, Pages 140-146

  Hsieh, Wan Ling ^a   Lin, Yin Ku ^b   Tsai, Chi Neu ^a   Wang, Ta Min ^b   Chen, Tzu Ya ^a   Pang, Jong Hwei S ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

CDC25B; EGFR; Epidermal keratinocytes; Indigo naturalis; Indirubin; Psoriasis

Indexed keywords

ANTIPSORIASIS AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INDIGO NATURALIS; INDIRUBIN; MESSENGER RNA; PROTEIN CDC25B; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PSORIASIS;

CDC25 PHOSPHATASES; CELL PROLIFERATION; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; EPIDERMIS; GENE EXPRESSION REGULATION; HUMANS; INDOLES; KERATINOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLANT EXTRACTS; PSORIASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; TIME FACTORS; TRANSFECTION;

EID: 84863880751     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.05.008     Document Type: Article

References (36)

1. Meier M., Sheth P.B. Clinical spectrum and severity of psoriasis. Curr Probl Dermatol 2009, 38:1-20.
2. Elder J.T. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun 2009, 10:201-209.
3. Roberson E.D., Bowcock A.M. Psoriasis genetics: breaking the barrier. Trends Genet 2010, 26:415-423.
4. Boneberger S., Rupec R.A., Ruzicka T. Complementary therapy for atopic dermatitis and other allergic skin diseases: facts and controversies. Clin Dermatol 2010, 28:57-61.
5. Reuter J., Wölfle U., Weckesser S., Schempp C. Which plant for which skin disease? Part 1: Atopic dermatitis, psoriasis, acne, condyloma and herpes simplex. J German Soc Dermatol 2010, 8:788-796.
6. Lin Y.K., Wong W.R., Chang Y.C., Chang C.J., Tsay P.K., Chang S.C., et al. The efficacy and safety of topically applied indigo naturalis ointment in patients with plaque-type psoriasis. Dermatology 2007, 214:155-161.
7. Lin Y.K., Chang C.J., Chang Y.C., Wong W.R., Chang S.C., Pang J.H. Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis. Arch Dermatol 2008, 144:1457-1464.
8. Lin Y.K., Leu Y.L., Yang S.H., Chen H.W., Wang C.T., Pang J.H. Anti-psoriatic effects of indigo naturalis on the proliferation and differentiation of keratinocytes with indirubin as the active component. J Dermatol Sci 2009, 54:168-174.
9. Timofeev O., Cizmecioglu O., Settele F., Kempf T., Hoffmann I. Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition. J Biol Chem 2010, 285:16978-16990.
10. Takemasa I., Yamamoto H., Sekimoto M., Ohue M., Noura S., Miyake Y., et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res 2000, 60:3043-3050.
11. Sasaki H., Yukiue H., Kobayashi Y., Tanahashi M., Moriyama S., Nakashima Y., et al. Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer. Cancer Lett 2001, 173:187-192.
12. Ngan E.S., Hashimoto Y., Ma Z.Q., Tsai M.J., Tsai S.Y. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003, 22:734-739.
13. Dong J., Zeng B.H., Xu L.H., Wang J.Y., Li M.Z., Zeng M.S., et al. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med 2010, 8:81.
14. Lavecchia A., Di Giovanni C., Novellino E. Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review. Expert Opin Ther Patents 2010, 20:405-425.
15. Brisson M., Nguyen T., Vogt A., Yalowich J., Giorgianni A., Tobi D., et al. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Mol Pharmacol 2004, 66:824-833.
16. 125I]epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol 1986, 86:260-265.
17. Anderson K.S., Petersson S., Wong J., Shubbar E., Lokko N.N., Carlström M., et al. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol 2010, 163:1085-1089.
18. Jones P.H., Watt F.M. Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 1993, 73:713-724.
19. Chomczynski P., Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 2006, 1:581-585.
20. Oguri T., Nemoto K., Bansal P., Wipf P., Lazo J.S. Induction of Cdc25B expression by epidermal growth factor and transforming growth factor-alpha. Biochem Pharmacol 2004, 68:2221-2227.
21. Nyati M.K., Morgan M.A., Feng F.Y., Lawrence T.S. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006, 6:876-885.
22. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc 2009, 4:44-57.
23. Miyoshi K., Takaishi M., Nakajima K., Ikeda M., Kanda T., Tarutani M., et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol 2011, 131:108-117.
24. Zhang Y., Opresko L., Shankaran H., Chrisler W.B., Wiley H.S., Resat H. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. BMC Cell Biol 2009, 10:78.
25. Johnston A., Gudjonsson J.E., Aphale A., Guzman A.M., Stoll S.W., Elder J.T. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. J Invest Dermatol 2011, 131:329-337.
26. Ben-Bassat H., Klein B.Y. Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr Pharm Des 2000, 6:933-942.
27. Wierzbicka E., Tourani J.M., Guillet G. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?. Br J Dermatol 2006, 155:213-214.
28. Mascia F., Mariani V., Girolomoni G., Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003, 163:303-312.
29. Segaert S., Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005, 16:1425-1433.
30. Lin Y.K., Chen H.W., Yang S.H., Leu Y.L., Huang Y.H., Yen H.C. Protective effect of indigo naturalis extract against oxidative stress in cultured human keratinocytes. J Ethnopharmacol 2012, 139:893-896.
31. Lin Y.K., Leu Y.L., Huang T.H., Wu Y.H., Chung P.J., Su Pang J.H., et al. Anti-inflammatory effects of the extract of indigo naturalis in human neutrophils. J Ethnopharmacol 2009, 125:51-58.
32. Chang H.N., Pang J.H., Yang S.H., Hung C.F., Chiang C.H., Lin T.Y., et al. Inhibitory effect of indigo naturalis on tumor necrosis factor-α-induced vascular cell adhesion molecule-1 expression in human umbilical vein endothelial cells. Molecules 2010, 15:6423-6435.
33. Marko D., Schätzle S., Friedel A., Genzlinger A., Zankl H., Meijer L., et al. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer 2001, 84:283-289.
34. Eisenbrand G., Hippe F., Jakobs S., Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 2004, 130:627-635.
35. Zhang X., Song Y., Wu Y., Dong Y., Lai L., Zhang J., et al. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer 2011, 129:2502-2511.
36. Miyoshi K., Takaishi M., Digiovanni J., Sano S. Attenuation of psoriasis-like skin lesion in a mouse model by topical treatment with indirubin and its derivative E804. J Dermatol Sci 2012, 65:70-72.